

## Lack of Effect of Carbonyl Cyanide *m*-Chlorophenylhydrazine on KB-5246 Accumulation by *Staphylococcus aureus*

YASUO KOTERA,<sup>1\*</sup> YOSHIMASA INOUE,<sup>1</sup> MASAMI OHASHI,<sup>1</sup> KEIZO ITO,<sup>1</sup> AND MATSUHISA INOUE<sup>2</sup>

*New Drug Research Laboratories, Kanebo, Ltd., 5-90, Tomobuchi-cho, 1-chome, Miyakojima-ku, Osaka 534,<sup>1</sup> and Gunma University, Maebashi, Gunma 371,<sup>2</sup> Japan*

Received 9 September 1991/Accepted 3 January 1992

**The accumulation of KB-5246 in a quinolone-susceptible strain of *Staphylococcus aureus* was about 70 times that of norfloxacin. Carbonyl cyanide *m*-chlorophenylhydrazine increased the accumulation of norfloxacin about eightfold, but it did not influence that of KB-5246. The low efflux of KB-5246 from *S. aureus* may contribute to its potent antibacterial activity.**

KB-5246, a new quinolone with a tetracyclic structure (9), has been demonstrated to have a broad spectrum of antibacterial activity. We have reported that the strong antibacterial activity of KB-5246 against gram-negative bacteria can be explained by its inhibition of DNA gyrase and its accumulation by both porin and non-porin pathways (8). However, the reason for the potent antibacterial activity of KB-5246 against gram-positive bacteria is still unknown.

In this study, we examined the activity of KB-5246 against *Staphylococcus aureus*, which was used as a representative gram-positive bacterium. The antibacterial activities of quinolones have been explained by their inhibitions of DNA gyrase and their permeation (1-7, 10, 11). We were unable to examine the inhibition of *S. aureus* DNA gyrase by KB-5246 because of difficulties in purifying DNA gyrase from clinical isolates of *S. aureus* (12). Therefore, to determine the reason for the potent antibacterial activity of KB-5246 against gram-positive bacteria, we compared the accumulation of KB-5246 and norfloxacin by a quinolone-susceptible strain of *S. aureus*.

KB-5246 and norfloxacin were synthesized in the Department of Chemistry of our laboratories. Methyltriphenylphosphonium (TPMP<sup>+</sup>) was purchased from Tokyo Kasei Co. The quinolone-susceptible clinical isolate used in this study, *S. aureus* INK-1, which was isolated during 1988 to 1989 in Japan, was donated by K. Deguchi.

MICs were determined by the twofold agar dilution method described previously (9).

The accumulation of KB-5246 and norfloxacin and the binding of TPMP<sup>+</sup> were measured by the method of Hirai et al. (6, 7), with the following modifications. Bacterial cells were grown to an optical density at 660 nm of 0.6. KB-5246, norfloxacin, or TPMP<sup>+</sup> was added to the bacterial suspension to a concentration of 10 µg/ml (final concentrations, KB-5246, 26 µM; norfloxacin, 31 µM; TPMP<sup>+</sup>, 28 µM), and the suspensions were incubated for 10 min at 37°C. In tests of the dose-response of accumulation, KB-5246 was added at concentrations of 0.05, 0.10, 0.50, 1.0, 5.0, and 10.0 µg/ml. After incubation, the cells were washed with 1 ml of saline by centrifugation, and the precipitated cells were suspended in 5% acetic acid, allowed to stand in boiling water for 5 min, and then centrifuged. The amount of KB-5246, norfloxacin, or TPMP<sup>+</sup> in the resulting supernatant was defined as that

amount accumulated by the cells. For evaluation of the energy-dependent efflux of quinolones, an uncoupler, carbonyl cyanide *m*-chlorophenylhydrazine (CCCP), was added 5 min before the addition of KB-5246, norfloxacin, or TPMP<sup>+</sup>. The concentration in the supernatant was determined by high-pressure liquid chromatography by using an Inertsil ODS-2 column (Gasukuro Kogyo Co.), a mobile phase composed of 5% acetic acid-methanol (85:15), a flow rate of 1.5 ml/min, and a detection wavelength of 270 nm at a column temperature of 40°C. All data on accumulation were means of two points.

Energy-dependent efflux has been reported to influence the accumulation of quinolones (2, 4). We examined the effect of CCCP on the binding of TPMP<sup>+</sup> or the accumulation of norfloxacin by *S. aureus* INK-1, because binding of TPMP<sup>+</sup> is known to be an indicator of the energized state in oxidative phosphorylation (5). TPMP<sup>+</sup> or norfloxacin was added at a concentration of 10 µg/ml. CCCP was added at a concentration of 200 µM 5 min before the addition of TPMP<sup>+</sup> or norfloxacin. The accumulation was measured after 10 min of incubation. Without CCCP, the accumulations of TPMP<sup>+</sup> and norfloxacin were 20.90 and 0.07 µg/mg of dry cell, respectively. With CCCP, TPMP<sup>+</sup> accumulation was not detected, and the accumulation of norfloxacin was 0.54 µg/mg of dry cell. Because the binding of TPMP<sup>+</sup> was completely inhibited by 200 µM CCCP, we used a CCCP concentration of 200 µM. The accumulation of norfloxacin was increased by the addition of 200 µM CCCP, as reported previously (13).

The dose-response curve for the accumulation of KB-5246 by the quinolone-susceptible strain (INK-1) of *S. aureus* is shown in Fig. 1. The accumulation increased linearly with an increase in the extracellular KB-5246 concentration over a range of extracellular concentrations of KB-5246 of 0.05 to 10.0 µg/ml. Moreover, the accumulation was not influenced by 200 µM CCCP over a range of extracellular KB-5246 concentrations of 0.10 to 10 µg/ml.

The accumulations of KB-5246 and norfloxacin by *S. aureus* INK-1 were compared (Fig. 2). The accumulation of KB-5246 by the clinical isolate (INK-1) which was susceptible to quinolones (norfloxacin MIC, 3.13 µg/ml; KB-5246 MIC, 0.10 µg/ml) was approximately 70-fold that of norfloxacin. Moreover, 200 µM CCCP increased the accumulation of norfloxacin in this quinolone-susceptible strain approximately eightfold but did not influence its accumulation of KB-5246. These results suggest that the ineffective efflux of

\* Corresponding author.




FIG. 1. Dose-response curve of the accumulation of KB-5246 by a quinolone-susceptible strain (INK-1) of *S. aureus*. KB-5246 was added at concentrations of 0.05, 0.10, 0.50, 1.0, 5.0, and 10 µg/ml. CCCP was added at a concentration of 200 µM 5 min before the addition of KB-5246. The accumulation was measured after 10 min of incubation.

KB-5246 from the quinolone-susceptible strain of *S. aureus* may be one factor responsible for the potent antibacterial activity of KB-5246. Norfloxacin might be effectively ejected by an energy-dependent efflux system.

In this study, we measured the accumulation of KB-5246 in *S. aureus* and the effect of CCCP on its accumulation to determine the reason for its potent antibacterial activity against gram-positive bacteria. We found that the accumulation of KB-5246 in the quinolone-susceptible strain was 70

times that of norfloxacin. One reason for its high accumulation was its ineffective efflux.

Recently, H. Yoshida et al. (13) established the sequence of a *norA* gene that encoded a membrane-associated active efflux pump. They reported that this efflux pump effectively excretes a hydrophilic agent but that it does not excrete a hydrophobic agent. Thus, the poor efflux of KB-5246 from *S. aureus* cells might be due to its hydrophobicity (8). S. Yoshida et al. (14) reported that one mechanism of resis-




FIG. 2. Accumulation of KB-5246 (A) and norfloxacin (B) by a quinolone-susceptible strain (INK-1) of *S. aureus*. KB-5246 or norfloxacin was added at a concentration of 10 µg/ml. CCCP was added at a concentration of 200 µM 5 min before the addition of KB-5246 or norfloxacin. The accumulation was measured after 10 min of incubation. Open columns, without CCCP; hatched columns, with 200 µM CCCP.

tance of *S. aureus* to quinolones is energy-dependent efflux. KB-5246 should be a useful tool for investigating the mechanism of resistance in these strains.

We thank T. Nose and G. Tsukamoto (Kanebo, Ltd.) for continuous encouragement. Y.K. thanks T. Kusunoki for technical assistance.

#### REFERENCES

1. **Bedard, J., S. Wong, and L. E. Bryan.** 1987. Accumulation of enoxacin by *Escherichia coli* and *Bacillus subtilis*. *Antimicrob. Agents Chemother.* **31**:1348–1354.
2. **Bedard, J., S. Wong, T. Schollaardt, and L. E. Bryan.** 1989. Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of *Escherichia coli*, *Pseudomonas aeruginosa*, and *Alcaligenes faecalis* to ciprofloxacin. *Antimicrob. Agents Chemother.* **33**:1457–1464.
3. **Chapman, J. S., and N. H. Georgopapadakou.** 1988. Routes of quinolone permeation in *Escherichia coli*. *Antimicrob. Agents Chemother.* **32**:438–442.
4. **Cohen, S. P., D. C. Hooper, J. S. Wolfson, K. S. Souza, L. E. McMurry, and S. B. Levy.** 1988. Endogenous active efflux of norfloxacin in susceptible *Escherichia coli*. *Antimicrob. Agents Chemother.* **32**:1187–1191.
5. **Higuti, T.** 1984. Conformational coupling in H<sup>+</sup>-pumps and ATP synthesis—its analysis with anisotropic inhibitors of energy transduction in oxidative phosphorylation. *Mol. Cell. Biochem.* **61**:37–61.
6. **Hirai, K., H. Aoyama, T. Irikura, S. Iyobe, and S. Mitsuhashi.** 1986. Differences in susceptibility to quinolones of outer membrane mutants of *Salmonella typhimurium* and *Escherichia coli*. *Antimicrob. Agents Chemother.* **29**:535–538.
7. **Hirai, K., H. Aoyama, S. Suzue, T. Irikura, S. Iyobe, and S. Mitsuhashi.** 1986. Isolation and characterization of norfloxacin-resistant mutants of *Escherichia coli* K-12. *Antimicrob. Agents Chemother.* **30**:248–253.
8. **Kotera, Y., M. Inoue, and S. Mitsuhashi.** 1990. Activity of KB-5246 against outer membrane mutants of *Escherichia coli* and *Salmonella typhimurium*. *Antimicrob. Agents Chemother.* **34**:1323–1325.
9. **Kotera, Y., and S. Mitsuhashi.** 1989. In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone. *Antimicrob. Agents Chemother.* **33**:1896–1900.
10. **Mitsuhashi, S.** 1988. Comparative antibacterial activity of new quinolone-carboxylic acid derivatives. *Rev. Infect. Dis.* **10**(Suppl. 1):S27–S31.
11. **Takahata, M., and T. Nishino.** 1988. DNA gyrase of *Staphylococcus aureus* and inhibitory effect of quinolones on its activity. *Antimicrob. Agents Chemother.* **32**:1192–1195.
12. **Ubukata, K., N. Itoh-Yamashita, and M. Konno.** 1989. Cloning and expression of the *norA* gene for fluoroquinolone resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **33**:1535–1539.
13. **Yoshida, H., M. Bougaki, S. Nakamura, K. Ubukata, and M. Konno.** 1990. Nucleotide sequence and characterization of the *Staphylococcus aureus norA* gene, which confers resistance to quinolones. *J. Bacteriol.* **172**:6942–6949.
14. **Yoshida, S., T. Kojima, M. Inoue, and S. Mitsuhashi.** 1991. Uptake of sparfloxacin and norfloxacin by clinical isolates of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **35**:368–370.